UAS
ALXN

United Asset Strategies’s Alexion Pharmaceuticals ALXN Stock Holding History

United Asset Strategies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,148
Closed -$804K – 237
2020
Q4 		$804K Sell
5,148
-80
-2% -$10.3K 0.13% 116
2020
Q3 		$598K Buy
5,228
+1,094
+26% +$118K 0.11% 121
2020
Q2 		$464K Sell
4,134
-169
-4% -$17.9K 0.09% 133
2020
Q1 		$386K Sell
4,303
-282
-6% -$27.7K 0.1% 135
2019
Q4 		$496K Buy
4,585
+105
+2% +$11.2K 0.1% 150
2019
Q3 		$439K Sell
4,480
-7,017
-61% -$791K 0.1% 140
2019
Q2 		$567K Buy
+11,497
New +$1.48M 0.13% 127

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

United Asset Strategies's ALXN Position: Q1 2021 in Review

United Asset Strategies sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 5,148 shares — an estimated $804K sold.

United Asset Strategies first reported a position in ALXN in Q2 2019 and held it in 7 quarters. The position peaked at $804K in Q4 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • United Asset Strategies reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • United Asset Strategies sold 5,148 Alexion Pharmaceuticals shares in Q1 2021, an estimated $804K.
  • United Asset Strategies first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 7 quarters.
  • United Asset Strategies's Alexion Pharmaceuticals position peaked at $804K in Q4 2020.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on United Asset Strategies's 13F filing for Q1 2021, filed 27 Apr 2021.